Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (373)	3/8/2006 9:48:39 AM
From: david nordic	Read Replies (1) \| Respond to of 447

2. Reason for the $100 cut in revenue guidance: OSIP underestimated the threat from an “early” (i.e. mid-2006) Lucentis launch and the off-label use of Avastin in AMD. Its too early to call. Some Insurance is not paying. AMD patient avg. age is 72. Safety risk labeling will be factor. Off label Avastin/Lucentis safety profile has just come to light prior to FDA/EMEA review. There is another webcast friday. 90% of the webcast was about Macugen.

To: DewDiligence_on_SI who wrote (373)	4/12/2006 1:09:28 PM
From: tuck	Read Replies (1) \| Respond to of 447

From DNA's quarterly PR: >>U.S. sales of Tarceva® (erlotinib) increased 94 percent to $93 million, from $48 million in the first quarter of 2005, its first full quarter of sales. Sequential quarter-over-quarter Tarceva sales increased 11 percent from fourth quarter 2005 sales of $84 million.<< Merrill Lynch described this as "in line." Looks as though you could have stuck to your short a little longer. Meanwhile, it'll be interesting to see if the May 30 calls I wrote expire worthless. Cheers, Tuck